Introduction
T2D, diabetes mellitus, T2D), T1D, hypoglycemic, Diabetes, diabetes
DIABETES, EVENTS, DIABETES MELLITUS, DIABETES
Treatment of patients with type 1 (T1D) and some type 2 (T2D) diabetes mellitus is based on insulin therapy in order to mimic the physiological pancreatic secretion according to a basal/bolus pattern obtained either by multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) with an external insulin pump. In a very large population-based study [However, the indications for an external pump therapy for non-pregnant adults with T1D has been summarized by the French Society for the Study of Diabetes [During the current decade, there has been several innovations in the management of diabetes, including insulin pumps improvement. Pumps have become smaller, less invasive and easier to use. They now offer the possibility to be equipped with sensors and integrated algorithms allowing closed-loop insulin delivery systems (“artificial pancreas”) [Conventional insulin pumps deliver insulin continuously using tubing and external catheter. These pumps have proved to be effective as intensive therapy of diabetes by improving the glycemic control and reducing hypoglycemic events [The A7+TouchCareThe aim of this real-life study was to collect performance, safety, tolerability and patient’ satisfaction with the A7+TouchCare pump system in patients with T1D and T2D after 3 months of use, in comparison with Omnipod